<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13088">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01660607</url>
  </required_header>
  <id_info>
    <org_study_id>BMT236</org_study_id>
    <secondary_id>SU-09142011-8407</secondary_id>
    <nct_id>NCT01660607</nct_id>
  </id_info>
  <brief_title>Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell</brief_title>
  <official_title>Phase I/II Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T Cell Depleted Graft With Simultaneous Infusion of Conventional T Cells and Regulatory T Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ginna Laport</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with hematologic malignancies undergoing allogeneic myeloablative (MA) HCT with
      a T cell depleted graft, the infusion of naturally occurring regulatory T cells  with
      conventional T cells  (T cell addback) in pre-defined doses and ratios will reduce the
      incidence of acute graft vs host disease while augmenting the graft vs leukemia effect and
      improving immune reconstitution.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>(Phase II) Event free survival post-HCT</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Myeloid Leukemia, Chronic</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndromes (MDS)</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the Phase I arm of the study the addition of planned numbers and ratios of Treg compared to Tcon will occur at defined time points after hematopoietic cell infusion. Each cohort will have 3 patients per group. The initial doses and ratios utilized will be 1 x 10^6/kg of T reg cells to 3x10^6/kg of Tcon cells at a 1:3 ratio. In order to progress to the next dose level, there must be no evidence of grade 3 or 4 acute GVHD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conventional T cells (Tcon) and Regulatory T cells (Treg)</intervention_name>
    <description>A baseline cell dose of conventional T cells of 1x10^6/kg will be used with escalation to the maximum tolerated dose up to 1x10^7/kg</description>
    <arm_group_label>Dose escalation</arm_group_label>
    <other_name>Purified regulatory T cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recipient Inclusion Criteria:

          -  Patients with the following diseases that are histopathologically confirmed are
             eligible

               -  Acute leukemia, primary refractory or beyond CR1

               -  Chronic myelogenous leukemia (accelerated, blast or second chronic phase)

               -  Myelodysplastic syndromes

               -  Non-Hodgkin lymphoma with poor risk features not suitable for autologous HCT

          -  Age &lt;= 60 yo

          -  Cardiac ejection fraction &gt;= 45%

          -  Lung diffusion capacity &gt;= 50%

          -  Calculated creatinine clearance  &gt;= 50 cc/min

          -  SGPT  and SGOT &lt;=  2.5 x ULN, unless elevated secondary to disease. Total bilirubin
             &lt;= 2 x ULN (patients with Gilbert's syndrome may be included at the discretion of the
             PI or where hemolysis has been excluded

          -  Availability of a 6/6 HLA matched sibling defined by Class I (HLA -A and B) serologic
             typing (or higher resolution) and Class II (HLA-DRB1) molecular typing.

          -  Karnofsky performance status &gt;=70%

          -  No prior myeloablative therapy or hematopoietic cell transplantation

        Recipient Exclusion Criteria

          -  Seropositive for any of the following: HIV ab, hepatitis B sAg , hep C ab

          -  Uncontrolled bacterial, viral or fungal infection defined as currently taking
             antimicrobial therapy and progression of clinical symptoms.

          -  Uncontrolled CNS disease involvement

          -  The recipient is pregnant or a lactating female

          -  Psychosocial circumstances that preclude the patient being able to go through
             transplant or participate responsibly in follow up care.

        Donor Inclusion Criteria

          -  Age &lt;= 75 years

          -  Karnofsky performance status of &gt;=70%

          -  Medical history and PE confirm good health status as defined by institutional
             standards

          -  Seronegative for HIV Ag, HIV 1 and HIV 2 ab, HTLV 1 and HTLV 2 ab hepatitis B sAg or
             PCR+ or  hepatitis C ab or PCR+ , negative for the Syphilis treponemal screen and
             negative for HIV 1 and hepatitis C by NAT (nucleic acid testing) within 30 days of
             apheresis collection

          -  Must be 6/6 matched sibling donor as determined by HLA typing

          -  Female donors of child-bearing potential must have a negative serum or urine beta-HCG
             test within three weeks of mobilization

          -  Capable of undergoing leukapheresis, have adequate venous access, and be willing to
             undergo insertion of a central catheter should leukapheresis via peripheral vein be
             inadequate

          -  The donor or legal guardian greater than 18 years of age, capable of signing an
             IRB-approved consent form.

        Donor Exclusion Criteria

          -  Evidence of active infection or viral hepatitis

          -  HIV positive

          -  Lactating female
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ginna G Laport</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lana Peysakhovich</last_name>
    <phone>650-721-3253</phone>
    <email>lpeysakh@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine Palo Alto, California, United States</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginna G Laport</last_name>
      <phone>650-723-0822</phone>
      <email>ginna.laport@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Rajni Agarwal-Hashmi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sally Arai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Benjamin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Johnston</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Lowsky</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert S Negrin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Sheehan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith Anne Shizuru</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Miklos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen-Kai Weng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 31, 2013</lastchanged_date>
  <firstreceived_date>August 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Ginna Laport</investigator_full_name>
    <investigator_title>Assoc Prof-Med Ctr Line</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
